Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | DRD1 | P21728 | 3/20 | 0.38 |
| ▸ | DRD5 | P21918 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749374 | 0.92 | PRCP (0.51) | PRCPPDE2ADRD2GAASLC6A4 | |
| SCHEMBL14749368 | 0.85 | PRCP (0.67) | PRCPDRD2DRD3HRH3HTR2A | |
| SCHEMBL14749404 | 0.85 | PRCP (0.45) | PRCPPDE2AHRH3 | |
| SCHEMBL14749367 | 0.84 | PRCP (0.54) | PRCPDRD2DRD3DRD1DRD5 | |
| SCHEMBL14749424 | 0.83 | LMNA (0.47) | PRCPPDE2AHRH3 | |
| SCHEMBL14749369 | 0.81 | PRCP (0.59) | PRCPPDE2ADRD2DRD3DRD4 | |
| SCHEMBL14737072 | 0.81 | PRCP (0.52) | PRCPPDE2ADRD2DRD3HRH3 | |
| SCHEMBL14749379 | 0.79 | PRCP (0.59) | PRCPSLC6A4SLC6A3HRH3 | |
| SCHEMBL14749377 | 0.77 | PRCP (0.51) | PRCPPDE2ADRD2DRD3DRD4 | |
| SCHEMBL14749344 | 0.77 | PRCP (0.53) | PRCPDRD2DRD3DRD4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885PDE2A 1477/4885DRD2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.